Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status

NCT01625286 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01625286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01625286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
October 3, 2012
Completion date
October 3, 2022
Enrollment
148 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic breast cancer, er+ve advanced or metastatic breast cancer